TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
31.00
+0.04 (0.13%)
At close: Nov 14, 2025, 4:00 PM EST
31.00
0.00 (0.01%)
After-hours: Nov 14, 2025, 7:43 PM EST
TG Therapeutics Revenue
TG Therapeutics had revenue of $161.71M in the quarter ending September 30, 2025, with 92.79% growth. This brings the company's revenue in the last twelve months to $531.90M, up 100.88% year-over-year. In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth.
Revenue (ttm)
$531.90M
Revenue Growth
+100.88%
P/S Ratio
8.51
Revenue / Employee
$1,573,663
Employees
338
Market Cap
4.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
| Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
| Dec 31, 2020 | 152.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TGTX News
- 12 days ago - TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows - Seeking Alpha
- 13 days ago - TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 19 days ago - TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI - GlobeNewsWire
- 7 weeks ago - New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment - GlobeNewsWire
- 2 months ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting - GlobeNewsWire
- 2 months ago - TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment - GlobeNewsWire
- 2 months ago - TG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha